Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ADVM

ADVM - Adverum Biotechnologies Inc Stock Price, Fair Value and News

$4.36 
Market Closed

Price Targets

ADVM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ADVM Price Action

Last 7 days

3.4%

Last 30 days

-0.7%

Last 90 days

21.0%

Trailing 12 Months

-25.1%

ADVM RSI Chart

ADVM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ADVM Valuation

Market Cap

96.3M

Price/Earnings (Trailing)

-0.52

Price/Sales (Trailing)

94.93

EV/EBITDA

-0.52

Price/Free Cashflow

-0.7

ADVM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

ADVM Fundamentals

ADVM Revenue

Revenue (TTM)

1.0M

ADVM Earnings

Earnings (TTM)

-184.8M

Earnings Growth (Yr)

-47.3%

Earnings Growth (Qtr)

3.13%

ADVM Profitability

EBT Margin

-13092.70%

Return on Equity

332.04%

Return on Assets

-255.24%

Free Cashflow Yield

-143.87%

ADVM Investor Care

Shares Dilution (1Y)

6.13%

Diluted EPS (TTM)

-8.59

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
2024001.0M1.0M
20233.6M3.6M3.6M3.6M
20213.6M5.5M6.5M7.5M
2019001.6M2.6M
20187.5M7.6M7.9M7.5M
20171.7M1.8M1.9M1.8M
20162.4M2.5M1.9M1.5M
2015745.0K813.0K1.6M2.3M
2014210.0K195.0K369.0K572.0K
2013142.5K255.0K367.5K480.0K
201200030.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Adverum Biotechnologies Inc

ADVM
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
 CEO
 WEBSITEhttps://adverum.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES123

Adverum Biotechnologies Inc Frequently Asked Questions

ADVM is the stock ticker symbol of Adverum Biotechnologies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Dec 09 2025, market cap of Adverum Biotechnologies Inc is 96.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Tue Dec 09 2025, ADVM's PE ratio (Price to Earnings) is -0.52 and Price to Sales (PS) ratio is 94.93. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADVM PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Adverum Biotechnologies Inc has provided -0.265 (multiply by 100 for percentage) rate of return.